Vilacto Bio Presents, In Cooperation With Danish Podiatrists, Its Latest Product: Vilact Cuticle Cream
COPENHAGEN, Denmark, July 11, 2017 (GLOBE NEWSWIRE) -- Vilacto Bio Inc. (OTC QB:VIBI), is pleased to present its latest product, Vilact Cuticle cream, developed in cooperation with Danish podiatrists. Lactoactive, the ingredient molecule in Vilact Cuticle cream, works to help with skin challenges, and Danish podiatrists have demonstrated its use with faster patient recovery.
Vilact Cuticle Cream contains Lactoactive®, “the super molecule” that makes a huge difference on skin issues as well as smoothing, moisturizing and beautifying the skin.
The Company plans to cooperate with doctors, podiatrists and other specialists in the development and success of its skin care products.
“This is another important step in our evolution as a skin care and Biotech Company and we are pleased to make this announcement," states Gert Anderson, CEO of Vilacto Bio Inc.
About Vilacto Bio Inc.:
Vilacto Bio Inc. (OTC QB:VIBI), is a biotech company that has developed the now fully patented Lactoactive® (Lactoactive super-molecule) that in numerous studies has demonstrated above average effect treating conditions such as inflammatory diseases, diabetes, psoriasis, skin aging, and skin issues in different levels. We aim to further develop our Lactoactive® molecule for the purpose of increasing the quality of our retail and medical skin cream products as well as licensing out our Lactoactive® molecule for the pharmaceutical industry.
Forward-Looking Statements & Disclaimers:
The information in this Press Release includes certain "forward-looking" statements within the meaning of the Safe Harbor provisions of Federal Securities Laws, as that term is defined in section 27a of the United States Securities Act of 1933, as amended, and section 21e of the United States Securities Exchange Act of 1934, as amended. Statements in this document, which are not purely historical, are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Investors are cautioned that such statements are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties, including the future financial performance of the Company. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it can give no assurance that such expectations or any of its forward-looking statements will prove to be correct. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of this release, and the Company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date of this release except as required by law.
Vilacto Bio Inc. The Seagram Building 375 Park Avenue, Suite 2607 New York City, NY 10152 Gert Andersen Phone: +1 646-893-7895 info@vilactobio.com www.vilactobio.com